Development of radiolabeled peptides to target p185HER2/neu receptors of cancer

Su, Zi-Fen

doi:10.1002/jlcr.1137

Labelled Comp Radiopharmac

2006

DOI: 10.1002/jlcr.1137

|View full text |Cite

Development of radiolabeled peptides to target p185HER2/neu receptors of cancer

Zi-Fen Su

Abstract: SummaryThe p185HER2/nue receptors which regulate the growth of cancer cells and are overexpressed in 20-30% of the cancers can be the markers for cancer diagnosis. This work describes the DTPA conjugation, Indium(III) complexes characterization,

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2007

2015

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, AHNP has a very short blood half-life (< 30 min). 37 Therefore, the free peptide would be mostly cleared from blood at the first measurement time point (i.e., 6 h after NP injection).…”

mentioning

confidence: 99%

Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells

Kievit

Kant

et al. 2015

Nanoscale

View full text Add to dashboard Cite

Nanoparticles (NPs) for targeted therapy are required to have appropriate size, stability, drug loading and release profiles, and efficient targeting ligands. However, many of existing NPs such as albumin, liposomes, polymers, gold NPs, etc. encounter size limit, toxicity and stability issues when loaded with drugs, fluorophores, and targeting ligands. Furthermore, antibodies are bulky and can greatly affect the physicochemical properties of the NPs, whereas many small molecule-based targeting ligands lack specificity. Here, we report utilization of biocompatible, biodegradable, small (~30 nm) and stable iron oxide NPs (IONPs) for targeted delivery of paclitaxel (PTX) to HER2/neu positive breast cancer using an anti-HER2/neu peptide (AHNP) targeting ligand. We demonstrate the uniform size and high stability of these NPs in biological medium, effective tumour targeting in live mice, as well as their efficient cellular targeting and selective killing in human HER2/neu-positive breast cancer cells.

show abstract

mentioning

confidence: 99%

Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells

Kievit

Kant

et al. 2015

Nanoscale

View full text Add to dashboard Cite

show abstract

Survey of the year 2006 commercial optical biosensor literature

Rich

Myszka

2007

J of Molecular Recognition

110

View full text Add to dashboard Cite

We identified 1219 articles published in 2006 that described work performed using commercial optical biosensor platforms. It is interesting to witness how the biosensor market is maturing with an increased number of instrument manufacturers offering a wider variety of platforms. However, it is clear from a review of the results presented that the advances in technology are outpacing the skill level of the average biosensor user. While we can track a gradual improvement in the quality of the published work, we clearly have a long way to go before we capitalize on the full potential of biosensor technology. To illustrate what is right with the biosensor literature, we highlight the work of 10 groups who have their eye on the ball. To help out the rest of us who have the lights on but nobody home, we use the literature to address common myths about biosensor technology.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Development of radiolabeled peptides to target p185HER2/neu receptors of cancer

Abstract: SummaryThe p185HER2/nue receptors which regulate the growth of cancer cells and are overexpressed in 20-30% of the cancers can be the markers for cancer diagnosis. This work describes the DTPA conjugation, Indium(III) complexes characterization,

Cited by 2 publications

References 25 publications

Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells

Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells

Survey of the year 2006 commercial optical biosensor literature

Contact Info

Product

Resources

About